Comparison of Serum Growth Factors and Tumor Markers as Prognostic Factors for Survival in Non-small Cell Lung Cancer

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5117-5123

  Nieder, Carsten ^a   Andratschke, Nicolaus ^a   Jeremic, Branislav ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Basic fibroblast growth factor; Non small cell lung cancer; Prognostic factors; Tumor marker; Vascular endothelial growth factor

Indexed keywords

ANTIGEN; BASIC FIBROBLAST GROWTH FACTOR; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; GROWTH FACTOR; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; GROWTH FACTOR BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REFERENCE VALUE;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; SERPINS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0842343488     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Albain KS, Crowley JJ, LeBlanc M et al: Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience. Am J Clin Oncol 9: 1618-1626, 1991.
2. Ramalingam S, Pawlish K, Gadgeel S et al: Lung cancer in young patients: Analysis of a surveillance, epidemiology, and end results database. Am J Clin Oncol 16: 651-657, 1998.
3. Werner-Wasik M, Scott C, Cox JD et al: Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LANSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48: 1475-1482, 2000.
4. Cox G, Jones JL, Andi A et al: A biological staging model for operable non-small cell lung cancer. Thorax 56: 561-566, 2001.
5. Salgia R, Harpole D, Herndon JE 2nd et al: Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res 21: 1241-1246, 2001.
6. Wieskopf B, Demangeat C, Purohit A et al: Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Chest 108: 163-169, 1995.
7. Takahama M, Tsutsumi M, Tsujiuchi T et al: Frequent expression of the vascular endothelial growth factor in human non-small cell lung cancers. Jpn J Clin Oncol 28: 176-18, 1998.
8. Imoto H, Osaki T, Taga S et al: Vascular endothelial growth factor expression in non-small cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115: 1007-1014, 1998.
9. Volm M, Koomägi R and Mattern J: PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 19: 651-656, 1999.
10. Shou Y, Hirano T, Gong Y et al: Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small cell lung cancer. Br J Cancer 85: 1706-1712, 2001.
11. Ito H, Oshita F, Kameda Y et al: Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep 9: 119-123, 2002.
12. Minami K, Saito Y, Imamura H et al: Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinomas of the lung. Lung Cancer 38: 51-55, 2002.
13. Brattstrom D, Bergqvist M, Hesselius P et al: Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumors and poorer survival in non-small cell lung cancer patients. Lung Cancer 37: 57-63, 2002.
14. Niklinski J, Burzykowski T, Niklinska W et al: Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. Eur Respir J 12: 1424-1428, 1998.
15. Nisman B, Lafair J, Heching N et al: Evaluation of tissue polypeptide specific antigen, Cyfra 21-1, and carcinoembryonic antigen in non-small cell lung carcinoma. Cancer 82: 1850-1859, 1998.
16. Pujol JL, Boher JM, Grenier J et al: Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31: 221-23, 2001.
17. Suzuki K, Nagai K, Yoshida J et al: Conventional clinicopathologic prognostic factors in surgically resected non-small cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 86: 1976-1984, 1999.
18. Reinmuth N, Brandt B, Semik M et al: Prognostic impact of Cyfra 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36: 265-270, 2002.
19. Kashiwabara K, Nakamura H and Esaki T: Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels. Clin Chim Acta 294: 105-113, 2000.
20. Kulpa J, Wojcik E, Reinfuss M et al: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48: 1931-1937, 2002.
21. Hirashima T, Takada M, Komiya T et al: Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 18: 4713-4716, 1998.
22. Hatzakis KD, Froudarakis ME, Bouros D et al: Prognostic value of serum tumor markers in patients with lung cancer. Respiration 69: 25-29, 2002.
23. Szturmowicz M, Sakowicz A, Rudzinski P et al: The clinical value of Cyfra 21-1 estimation for lung cancer patients. Int J Biol Markers 11: 172-177, 1996.
24. Pujol JL, Grenier J, Parrat E et al: Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 154: 725-733, 1996.
25. Foa P, Fornier M, Miceli R et al: Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 19: 3613-3618, 1999.
26. Brechot JM, Chevret S, Nataf J et al: Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 33: 385-39, 1997.
27. Diez M, Torres A, Maestro ML et al: Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 73: 1248-1254, 1996.
28. Laack E, Kohler A, Kugler C et al: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 13: 1550-1557, 2002.
29. Joensuu H, Anttonen A, Eriksson M et al: Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62: 5210-5217, 2002.
30. Ueno K, Inoue Y, Kawaguchi T et al: Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 31: 213-219, 2001.
31. Lee DY, Kim SJ and Lee YC: Serum insulin-like growth factor (IGF)-1 and IGF-binding proteins in lung cancer patients. J Korean Med Sci 14: 401-404, 1999.
32. Nieder C, Nestle U, Ukena D et al: Tumor markers as prognostic factors in non-small cell lung cancer (German). Strahlenther Onkol 171: 587-593, 1995.
33. Sawabata N, Ohta M, Takeda S et al: Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 74: 174-179, 2002.
34. Vassilakopoulos T, Troupis T, Sotiropoulou C et al: Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer 32: 137-144, 2001.
35. Thames HD, Petersen C, Petersen S et al: Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther Onkol 178: 411-421, 2002.
36. Brundage MD, Davies D and Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057, 2002.
37. Hotta K, Segawa Y, Takigawa N et al: Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer. Anticancer Res 20: 2177-2180, 2000.
38. Moro D, Villemain D, Vuillez JP et al: CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 13: 169-176, 1995.
39. Rubins JB, Dunitz J, Rubins HB et al: Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 116: 412-416, 1998.